Compugen Ltd
CGEN
Market Cap$138.4M
Close$
$2.54
97.1% upside
Current Fair Value
97.1% upsideUndervalued by 97.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $138.40 Million |
|---|---|
| Enterprise Value | $132.71 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.16 |
| Beta | 3.2 |
| Outstanding Shares | 89,538,891 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.31 |
|---|---|
| PEG | 8.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.22 |
| Enterprise Value to EBIT | 12.55 |
| Enterprise Value to Net Income | 82 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...